Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Name: Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
Published: 2026
License: Public Domain

National Cancer Institute (NCI) · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia, myelodysplastic syndrome, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Related documents